Effect of parenteral administration of GM1 on cytokines and anti-ganglioside antibody patterns. Preliminary report in normal human individuals.
To assess the effects of monosialoganglioside GM1 on some immunological parameters, 12 healthy men were treated with 100 mg GM1 i.m. daily for 15 days. Before and after treatment, the following were studied: (1) serum levels of antibodies against GM1, asialo-GM1 (aGM1), GM2 and GD1b; (2) serum levels of interleukin (IL)-1 beta, IL-2, soluble IL-2 receptor (sIL-2R), tumor necrosis factor-alpha (TNF-alpha), and interferon-gamma (IFN-gamma); (3) IL-1 beta and TNF-alpha production by peripheral blood monocytes (PBMO). Anti-ganglioside antibody and cytokine serum levels were not affected by exogenous GM1 administration with the exception of a transient increase in anti-GM1 antibody titer observed in one subject. In addition, no inhibition of IL-1 beta and TNF-alpha production by PBMO was observed. These preliminary data do not support a potential immunogenic or immunomodulatory function for in vivo administered GM1.
Gallo
P
P
2nd Department of Neurology, University of Padova, School of Medicine, Italy.
Piccinno
M G
MG
Tavolato
B
B
Innocenti
M
M
Callegaro
L
L
Kirschner
G
G
Bruno
R
R
Chizzolini
C
C
Fiori
M G
MG
D000293:Adolescent; D000328:Adult; D000906:Antibodies / Q000032:analysis*; D002855:Chromatography, Thin Layer; D016207:Cytokines / Q000097:blood*; D004797:Enzyme-Linked Immunosorbent Assay; D005677:G(M1) Ganglioside / Q000494:pharmacology*; D005732:Gangliosides / Q000276:immunology*; D006801:Humans; D007263:Infusions, Parenteral; D012016:Reference Values
D000906:Antibodies; D016207:Cytokines; D005732:Gangliosides; D005677:G(M1) Ganglioside